

The 8th Annual Glaucoma 360

New Horizons Forum will be hosted in California on February 1, 2019.

On February 1, 2019, Glaucoma Research Foundation (GRF) will host the 8th annual Glaucoma 360 New Horizons Forum in San Francisco.

Cofounded by Adrienne Graves, PhD, a member of the GRF board, and Andrew G. Iwach, MD, director of the Glaucoma Center of San Francisco and chairman of GRF's board, the goal of this collaborative meeting is to highlight innovations in glaucoma and unite the various elements needed to bring a new idea into clinical use.

Since its inception in 2012, this meeting has grown substantially, attracting key clinical, scientific, industry, financial, and regulatory leaders from across the United States and around the world.

Dr. Graves said, "We have numerous companies presenting their new technologies and approaches to glaucoma care (Figure 1). At the same time, we have venture capitalists looking for their next investment opportunities, and the FDA is here to provide useful tools and advice to the innovators to help them take these new ideas into practice (Figure 2). For both doctors and patients, the glaucoma landscape has changed dramatically since we started Glaucoma 360, and each year there have been significant new developments. We are anxious to learn what is new at our 2019 meeting."

Dr. Iwach added, "Over the past 8 years, the New Horizons Forum has provided a critical venue to get everyone in the glaucoma space together to stimulate and facilitate key discussions and connections. It's another unique approach for the GRF to serve as a catalyst in the development of new glaucoma therapies that will help patients not only preserve their vision, but GRF is also looking at ways to restore vision."

Janey Wiggs, MD, PhD, from Harvard Medical School, the Howe Laboratory, and Massachusetts Eye and Ear in Boston, will deliver the Drs. Henry and Frederick Sutro Memorial Lecture, the Forum's keynote address on the impact of genetics on glaucoma.

Topics at the 2019 meeting will include

- new developments in glaucoma devices,
- drug delivery and pharmaceuticals, and
- panel presentations from nationally and internationally respected leaders from venture capital, pharmaceutical, and medical device companies.

Special sessions will also be included to highlight advances in telemedicine and vision restoration.

Glaucoma 360 Steering Committee member Ruth Williams, MD, stressed the importance of clinician participation at this type of meeting: "Attending the New Horizons Forum provides the opportunity to network with individuals who are committed to



Figure 1. More than 20 presenting companies will be invited to participate to highlight their innovations in new glaucoma devices, drug delivery, and pharmaceuticals.



Figure 2. Kuldev Singh, MD, MPH, (center) from Stanford University in California, will comoderate the FDA session for the 2019 meeting. Malvina Eydelman, MD, (left) and Wiley A. Chambers, MD, (right) from the FDA, will be invited to participate in the panel discussion.

bringing new glaucoma therapies to our patients. Each year, I take away a great sense of hope and excitement about the future."

New Horizons Forum is the centerpiece of Glaucoma 360, GRF's signature 3-day series of events planned for January 31 to February 2, 2019. Additional activities include the Annual Gala to benefit GRF's science and patient education programs, the 23rd annual Glaucoma Symposium CME, and the 4th Annual Optometric Glaucoma Symposium. ■